| Description |
The leadership of the Pharmaceutical Compliance Forum (PCF), the sponsor of the Sixth Annual Pharmaceutical Regulatory and Compliance Congress, seeks to transform the event to reflect a new style of learning and knowledge exchange. To that end, a PCF special planning committee has been charged with the transformation of the Pharma Congress. Under the leadership of the PCF special planning committee, the following initiatives have been put in place:
The Pharma Congress will address the top five pharmaceutical compliance issues in 2006. Harvard Law Professor Arthur Miller will facilitate the discussion of these key compliance challenges. Discussion and problem solving around these key issues will be woven throughout the conference.
The Pharma Congress will be interactive. In the plenary sessions each attendee will have a Meridia Audience response device with which he or she will be able to vote on questions put by the faculty. The attendee responses will be immediately projected on the session screens.
The Pharma Congress will be built around a sophisticated hypothetical exercise that will continue throughout the conference. The hypothetical will include a variety of factual scenarios relating to issues raised by the top five pharmaceutical compliance issues in 2006. Attendees will be challenged to apply their new knowledge to specific hypothetical fact circumstances. Results of the hypothetical will be shared on the last day of the conference.
Pharma Congress track sessions will be longer and will permit substantive learning and knowledge exchange, as well as the application of these bodies of knowledge to the changing Pharma Congress hypothetical.
The Pharma Congress will feature two unique networking reception opportunities. The Monday evening opening networking reception will feature an opportunity to meet a number of key federal and state regulators and Capitol Hill staff specializing in pharmaceutical policy. The Tuesday networking reception will feature the exchange and presentation of company Codes of Conduct at poster boards throughout the Pharma Congress Exhibit Hall.
The Pharma Congress will feature an extraordinary series of keynote speakers.
Who Should Attend
Pharmaceutical and Health
Care Executives and Board Members
Compliance Executives
Health Plan, Health System and Physician Organization
Medical Directors
Physicians
Pharmacists
Purchasers, including Private Employers and Public Purchasers
Pharmaceutical Manufacturers
Generic Pharmaceutical
Manufacturers
Site Management Organizations
Clinical Research Organizations
Pharmacy Benefit
Management Companies
Health Plans and Health Insurers
Wholesale, Retail, Mail Order and Internet Pharmacies
Health Care Attorneys and In-house Counsel
Compliance Officers
Privacy Officers
Ethics Officers
Food and Drug Law Attorneys
Pharmaceutical Consultants
Investment Bankers
Venture Capitalists
Health Care Regulators and Policy Makers
Health Services Researchers and Academics
Auditors
The Congress Goals and Objectives
To identify and analyze the top five pharmaceutical compliance issues for 2006
To utilize a hypothetical case study of a pharmaceutical manufacturer confronting a variety of regulatory and compliance challenges as a means of assessing risks and sharing best practice responses
To freely exchange company codes of conduct as a means of sharing compliance best practices
To provide a forum for leading regulators and qui tam counsel to express views and concerns in order to enhance communication among actors in the compliance field
About the Pharmaceutical Compliance Forum
The Pharmaceutical Compliance Forum (PCF) is a coalition of senior compliance officials and legal counsel from more than 50 of the largest pharmaceutical manufacturers. The PCF was founded in early-1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The organization is open to others in the industry and has more than doubled in membership since its founding. The members meet twice a year, for one to two days, focusing on open and informal sharing of compliance information, best practices, and current developments in the field. For membership information, contact Arjun Rajaratnam, Esq., Vice President and Compliance Officer, Global Pharmaceuticals, GlaxoSmithKline at 919-483-9938 or Arjun.X.Rajaratnam@gsk.com.
PCF Special Planning Committee
Arjun Rajaratnam, JD, Vice President and Compliance Officer, Global Pharmaceuticals, GlaxoSmithKline (Co chair)
Brenton L. Saunders, JD, MBA, Senior Vice President, Global Compliance and Business Practices, Schering-Plough Corporation (Co chair)
Bert Weinstein, Esq., Vice President, Corporate Compliance, Purdue Pharma LP (Co chair)
John Alivernini, Esq., Vice President and Chief Compliance Officer, Wyeth Pharmaceuticals
John T. Bentivoglio, Esq., Partner, King & Spalding LLP
David B. Chandler, Ph.D., DABT, Manager, Compliance, 3M Pharmaceuticals
Anthony L. Farino, Partner, US Leader, Life Sciences Advisory Practice, PricewaterhouseCoopers LLP
Peter N. Grant, JD, Ph.D., President, Health Care Conference Administrators, LLC
Keith M. Korenchuk, JD, MPH, Partner, McGuire Woods
Steve Mohr, Esq., Deputy Compliance Officer, AstraZeneca
Lori Queisser, Vice President and Chief Compliance Officer, Eli Lilly and Company
Catherine A. Sazdanoff, Divisional Vice President, Ethics and Compliance, Abbott Laboratories
Michael Shaw, Deputy Compliance Officer, Novartis Pharmaceuticals Corporation
Paul J. Silver, Investigative and Dispute Services, Ernst & Young LLP
Jonathan K. Sprole, Vice President and Deputy General Counsel and Chief Compliance Officer, Bristol-Myers Squibb Company
Sheryl Vacca, CHC, West Coast Life Science and Health Care Regulatory Practice Leader, Deloitte & Touche LLP
|
|
